Cytek Biosciences, Inc.
CTKB
$3.96
$0.195.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -28.98% | 18.83% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -28.98% | 18.83% | |||
| Cost of Revenue | -21.79% | 18.24% | |||
| Gross Profit | -35.37% | 19.36% | |||
| SG&A Expenses | 2.02% | 6.23% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.58% | 10.17% | |||
| Operating Income | -230.05% | 39.14% | |||
| Income Before Tax | -330.98% | 48.11% | |||
| Income Tax Expenses | -96.27% | 1,847.93% | |||
| Earnings from Continuing Operations | 57.20% | -704.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 57.20% | -704.60% | |||
| EBIT | -230.05% | 39.14% | |||
| EBITDA | -348.84% | 49.16% | |||
| EPS Basic | 57.37% | -701.63% | |||
| Normalized Basic EPS | -328.43% | 48.29% | |||
| EPS Diluted | 56.38% | -701.63% | |||
| Normalized Diluted EPS | -328.43% | 48.29% | |||
| Average Basic Shares Outstanding | 0.42% | 0.48% | |||
| Average Diluted Shares Outstanding | 0.42% | 0.48% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||